Amrutanjan Health Care Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹135 Cr +14.4% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
AH

Amrutanjan Health Care Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Amrutanjan Health Care Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹118Cr
+7.3% YoY
+25.5% QoQ
Net profit
₹14Cr
+16.7% YoY
+75% QoQ
Margin
14%
+2 pp YoY
+5 pp QoQ

Based on Amrutanjan Health Care Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹510
Market cap₹1.4K Cr
P/E23.0

The short version

Q2 FY26 Revenue from Operations: Rs. 117.70 Cr, up 7.08% YoY (Page 22). Q2 FY26 EBITDA: Rs. 24.42 Crores, up 19.95% YoY (from Rs. 20.35 Crores in Q2 FY25) [Page 31].

From Amrutanjan Health Care Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q2 FY26 Revenue from Operations: Rs. 117.70 Cr, up 7.08% YoY (Page 22)
  • Q2 FY26 Gross Sales: Rs. 132.49 Cr, up 9.76% YoY (Page 22)
  • Q2 FY26 Net Sales - OTC: Rs. 112.80 Cr, up 6.15% YoY (Page 23)
  • Q2 FY26 Net Sales – Comfy: Rs. 32.78 Cr, slight decline vs Rs. 33.00 Cr YoY (Page 23)
  • Q2 FY26 Gross Sales - Beverages: Rs. 5.25 Cr, up 33.93% YoY (Page 24)
  • H1 FY26 Revenue from Operations: Rs. 211.75 Cr, up 9.35% YoY (Page 25)
  • H1 FY26 Gross Sales: Rs. 239.68 Cr, up 11.86% YoY (Page 25)
  • H1 FY26 Net Sales - OTC: Rs. 198.38 Cr, up 10.89% YoY (Page 26)
  • H1 FY26 Net Sales – Comfy: Rs. 61.39 Cr, up 3.04% YoY (Page 26)
  • Management commentary notes softer Q2 topline due to new GST law effective late September (Page 30)

2 more points from Amrutanjan Health Care Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Sanitary napkin plant:
  • - Will be commissioned by late Q4 FY26
  • - Expected to be a strong enabler of Comfy brand profitability and strategic supply
  • SAP Implementation for Comfy Plant:

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Amrutanjan Health Care Ltd said on order book & pipeline — free account, 30 seconds.

Amrutanjan Health Care Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Amrutanjan Health Care Ltd Q2 FY26 results — key figures

Amrutanjan Health Care Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue118110+7.3%94+25.5%
Operating profit (EBITDA)1714+21.4%8+112.5%
Operating margin14%12%+2 pp9%+5 pp
Profit before tax1916+18.8%11+72.7%
Net profit (PAT)1412+16.7%8+75%
EPS (₹)4.834.08+18.4%2.87+68.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹135 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Amrutanjan Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Amrutanjan Health Care Ltd Q2 FY26 results?

Q2 FY26 Revenue from Operations: Rs. 117.70 Cr, up 7.08% YoY (Page 22). Q2 FY26 EBITDA: Rs. 24.42 Crores, up 19.95% YoY (from Rs. 20.35 Crores in Q2 FY25) [Page 31].

What is Amrutanjan Health Care Ltd share price analysis?

Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.

Is Amrutanjan Health Care Ltd planning capital expenditure?

Sanitary napkin plant: - Will be commissioned by late Q4 FY26 - Expected to be a strong enabler of Comfy brand profitability and strategic supply - SAP Implementation for Comfy Plant: - In progr

Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.